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We report a new Streptomyces species named S. formicae that was isolated from the African fungus-growing plant-ant 
Tetraponera penzigi and show that it produces novel pentacyclic polyketides that are active against MRSA and VRE. The 
chemical scaffold of these compounds, which we have called the formicamycins, is similar to the fasamycins identified 
from the heterologous expression of clones isolated from environmental DNA, but has significant differences that allow 
the scaffold to be decorated with up to four halogen atoms. We report the structures and bioactivities of 16 new 
molecules and show, using CRISPR/Cas9 genome editing, that biosynthesis of these compounds is encoded by a single type 
2 polyketide synthase biosynthetic gene cluster in the S. formicae genome. Our work has identified the first antibiotic from 
the Tetraponera system and highlights the benefits of exploring unusual ecological niches for new actinomycete strains 
and novel natural products. 
 
Introduction 
Over half of the antibiotics in clinical use are derived from the 
natural products (secondary metabolites) of Streptomyces 
bacteria and their close relatives, and most of these were 
introduced into the clinic during a ‘golden age’ of antibiotic 
discovery between 1940 and 1960.
1
 The misuse of antibiotics 
over the last 50 years has led to an alarming rise in 
antimicrobial resistance (AMR) which is arguably the greatest 
medical challenge humans will face this century. Recently, 
however, the advent of facile, large-scale genome sequencing 
and the discovery of new antibiotic-producing strains in under-
explored environments has reinvigorated the field of natural 
products discovery. The wealth of genomic data now available 
has demonstrated that Streptomyces and other filamentous 
actinomycetes have the capacity to produce many more 
natural products than are identified after culturing in the 
laboratory: typically only 10-25% of their identifiable 
biosynthetic gene clusters (BGCs) are expressed under 
standard laboratory conditions and new classes of BGC remain 
to be discovered.
2,3
 
      We have been exploring the chemical ecology of protective 
mutualisms formed between actinomycete bacteria and 
fungus-growing insects in order to understand how these 
associations are formed and to explore this niche as a 
potential source of new antibiotics.
4
 In addition to the fungus-
growing attine ants of South and Central America, which use 
actinomycete-derived antibiotics in their fungi-culture,
5,6
 it was 
recently discovered that many plant-ants also cultivate 
fungi.
7,8,9
 Plant-ants live in a mutualism with their host plant 
and provide protection from larger herbivores. In return, the 
host plants have evolved specialised hollow structures called 
domatia that house and protect the ants.
10
 South American 
Allomerus plant-ants and African Tetraponera plant-ants both 
grow fungi inside their domatia and they are associated with 
antibiotic-producing actinomycete bacteria.
11,12 
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      We previously reported the isolation of filamentous 
actinomycete bacteria, including Streptomyces and 
Saccharopolyspora strains, from the domatia and worker ants 
of Tetraponera penzigi plant-ants collected in Kenya.
12
 
Genome sequencing of these strains allowed us to identify 
new species with genomes encoding novel and/or atypically 
large numbers of BGCs based on antiSMASH analysis.
13
 We 
consider strains containing significantly higher numbers of 
BGCs than typical strains (for Streptomyces sp. this is in the 
range 30-35) to be ‘talented’ with respect to their potential for 
yielding new natural products. One such organism, which we 
designate Streptomyces formicae, also displayed a unique 
antagonistic activity against pathogenic drug resistant bacteria 
and fungi, including methicillin resistant Staphylococcus aureus 
(MRSA) and the multidrug resistant fungal pathogen 
Lomentospora prolificans.
14
 Subsequent bioassay guided 
fractionation using the sensitive test strain Bacillus subtilis led 
to the isolation and structural elucidation of thirteen new 
polyketide natural products that share a rare pentacyclic 
structure, some of which contain up to four chlorine atoms. 
These compounds fall into two groups. The first group (1-3) 
have an aromatic C-ring structure with sp
2
 carbon atoms at 
C10/C19, and lack any formal chiral centres. We have named 
these compounds fasamycin C-E respectively given their very 
close structural similarity to fasamycins A and B described 
previously from heterologous expression of a clone expressing 
a type 2 polyketide synthase (PKS) BGC isolated from an 
environmental DNA derived library.
15
 In contrast, compounds 
4-13 are highly modified compared to the fasamycins with a 
non-aromatic C-ring and chiral centres at C10 and C19. We 
have named this group of compounds the formicamycins 
because they are the first natural products to be characterised 
from S. formicae and are structurally and biosynthetically distinct 
from the fasamycins (see below). Supplementation of the growth 
medium with sodium bromide resulted in the incorporation of 
bromine to yield three additional formicamycin congeners (14-
16). 
      The formicamycins and fasamycins are active against 
clinical isolates of MRSA and vancomycin resistant enterococci 
(VRE), but do not display Gram-negative bacteria or antifungal 
activity. The availability of sixteen congeners allowed their 
structure-activity relationship (SAR) to be examined. We then 
grew MRSA for 20 generations in the presence of sub-
inhibitory concentrations of three formicamycins and re-
determined the MICs for MRSA. These assays showed that 
MRSA does not easily acquire spontaneous resistance to 
formicamycins, at least under the conditions tested. Finally, we 
show, using CRISPR/Cas9 genome editing, that biosynthesis of 
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these compounds is encoded by a type 2 PKS BGC in the S. 
formicae chromosome, and that re-introduction of this BGC 
restores biosynthesis of formicamycins in S. formicae. 
Identification of the formicamycin BGC allowed us to propose 
a plausible biosynthetic pathway. Deletion of forV encoding a 
putative flavin dependent halogenase abolished the 
production of any halogenated molecules and stalled the 
biosynthetic pathway at the fasamycin congener stage (1-3) 
indicating halogenation is a critical step required for further 
post-PKS modification to yield the formicamycin scaffold. 
Results and discussion 
Discovery of Streptomyces formicae: a talented new species 
We previously isolated a number of filamentous actinomycete 
strains from the domatia and worker ants of the African 
Tetraponera penzigi-Acacia plant-ant mutualism.
12
 On the 
basis of 16S rDNA sequencing and morphological 
characteristics we chose six individual strains for genome 
sequencing using the Pacific Biosciences RSII platform with 
assembly using the HGAP2 pipeline. The resulting high-quality 
assemblies were analysed using the genome mining platform 
antiSMASH 3.0.
13
 One isolate in particular caught our attention 
as its genome harbours at least 39 BGCs and extracts derived 
from growth on agar plates showed promising bioactivities in 
anti-infective assays against B. subtilis and the fungal 
pathogens Candida albicans CA6
16
 and Lomentospora 
prolificans CBS116904 (see below). These results prompted us 
to examine the relative genetic relationship with sequenced 
streptomycetes, for which there are now almost 800 complete 
and draft genome sequences available (ESI Fig. S1). On the 
basis of 16S RNA sequence analysis this strain possesses a 
unique lineage and is most closely related to Streptomyces sp. 
NRRL S-920, which was originally isolated from a soil sample of 
unknown origin. A more detailed comparison of atpD, rpoB 
and three other widely used phylogenetic markers, gyrA (DNA 
gyrase subunit A), recA (recombination protein) and trpB 
(tryptophan biosynthesis) revealed a 95% shared nucleotide 
identity between concatenated atpD-gyrA-recA-rpoB-trpB and 
Streptomyces. sp. NRRL S-920, suggesting this strain represents 
a new species. Given that it was isolated from T. penzigi 
worker ants, we suggest the name Streptomyces formicae. 
S. formicae produces antibacterial and antifungal natural products 
Primary bioassays using B. subtilis, C. albicans and L. prolificans 
indicated that S. formicae produces compounds with 
antibacterial and antifungal activity when grown on solid 
medium. Fractionation over silica gel showed that these 
activities could be separated and high-resolution LCMS 
analysis suggested the presence of novel metabolites in the 
fractions exhibiting distinct antibacterial and antifungal 
activities. Very few agents have been described that are active 
against the emerging multidrug resistant fungal pathogen L. 
prolificans, and the isolation and characterization of the 
antifungal metabolites will be reported elsewhere. Further 
metabolomics analysis of the antibacterial fraction suggested a 
family of structurally related molecules (congeners) which 
correlated with the bioactivity against B. subtilis. In order to 
isolate sufficient material for detailed structural and biological 
analysis their production on MS agar was scaled up (as 
detailed in ESI) to yield methanol extracts containing the target 
molecules. This included one experiment where the chemical 
elicitor sodium butyrate was added to the MS agar and led to 
the significantly enhanced production of the otherwise trace 
congener 1 (ESI Fig. S2).
17
 Purification of the resulting extracts 
was achieved using a combination of normal phase, reversed-
phase and size exclusion chromatography and led to the 
isolation of 13 individual molecules (1-13) in amounts of 
between 0.3 and 18 mg (see ESI for full details). As there are 
several reports demonstrating that bromine can substitute for 
chlorine in microbial natural products, when provided to 
growing cultures at appropriate levels,
18,19
 we repeated the 
production experiment but grew S. formicae on MS agar 
containing sodium bromide (2 mM) and showed by LCMS that 
three new brominated congeners were produced (14-16). This 
experiment was scaled up and small amounts (< 1 mg) of 
metabolites 14 and 15 were isolated while 16 was only 
detected by MS due to very low levels of production and the 
structure is inferred. The molecular formulae of all compounds 
1-16 were measured using high-resolution MS and their 
chemical structures determined using 1D and 2D NMR 
spectroscopy as described below (see Fig. 1 and Fig. 2). 
Structural elucidation of the formicamycins and new fasamycins 
Formicamycin B (5) was isolated first and its structure 
determined. The UV spectrum showed absorption maxima at 
235 and 286 nm which is characteristic of all formicamycin 
congeners. High-resolution ESI-MS indicated a molecular 
formula of C29H26Cl2O8 (calculated [M + H]
+
 = 573.1077; 
observed [M + H]
+
 = 573.1072; Δ = -0.96 ppm), suggesting 
sixteen degrees of unsaturation. The 
13
C NMR data was 
consistent with this and showed two carbonyl carbons at δC 
195.3 and 198.6 ppm, three methyl carbons at δC 18.3, 29.2 
and 34.2 ppm, two methoxy signals at δC 56.3 and 57.3 ppm, 
one methylene at δC 30.2 ppm, and two signals consistent with 
sp
3
 quaternary carbons at δC 39.6 and 80.3 ppm. In addition, 
analysis of HSQC spectra indicated a sp
3
 tertiary carbon at δC 
49.0 ppm which was hidden due to the solvent peak of 
deuterated methanol. It also showed 18 sp
2
 carbons at δC 98.7 
– 168.0 ppm. The 
1
H NMR revealed the presence of five methyl 
singlets (δH 1.95, 1.40, 1.64, 3.63 and 3.90 ppm), two 
methylene proton double doublets (δH 2.77 ppm (dd, 18.94 Hz 
and 9.18 Hz) and 3.52 ppm (dd, 18.94 Hz and 6.66 Hz)), one 
aliphatic proton double doublet (δH 2.56 ppm (dd, 9.18 Hz and 
6.66 Hz)), two aromatic proton singlets (δH 6.51 and 6.73 
ppm), as well as two aromatic proton doublets (δH 6.14 ppm 
(d, 2.30 Hz) and 6.45 ppm (d, 2.29 Hz)). Analysis of the COSY 
spectrum gave limited data, meaning the majority of 
connections were made on the basis of HMBC correlations 
(Fig. 2). This led to three aromatic substructures consisting of 
all 29 carbon atoms, leaving the positions of two chlorine 
atoms and four hydroxyl groups unassigned. The signal at δC 
80.3 ppm for C10 is consistent with a sp
3
 carbon and was 
Page 3 of 11 Chemical Science
C
he
m
ic
al
S
ci
en
ce
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
Fe
br
ua
ry
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
5/
02
/2
01
7 
12
:1
6:
31
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C6SC04265A
Edge Article Chemical Science 
4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
assigned as a tertiary hydroxyl group. The signals for C5, C13, 
and C15 exhibit canonical phenol chemical shifts (δC 150–170 
ppm). Substructures containing ring As and B were connected 
by a key HMBC correlation between H24 and C6. Similarly, the 
resulting ring-AB substructure is connected to ring-C (see 
substructure rings C-E, Fig 2) by HMBC correlations between 
H20 and C8, C21 and C22, as well as the HMBC correlation 
between H19 and C21. The two chlorine atoms were therefore 
assigned to positions C2 and C22 (δC 113.9 and 121.8 ppm). 
The assignments are supported by the vicinal 
1
H-
1
H COSY 
correlations and NOESY correlations.  
      With the structure of 5 in hand we were able to readily 
assign the remaining structures as described in the ESI. NOESY 
correlations allowed us to link the methoxy at C5 with H4 (e.g. 
4, 6, 8-11 and 13). We could also use NOESY correlations to 
distinguish H14 and H16 once one was chlorinated, depending 
on their relationship to the gem-dimethyl group (e.g. 7, 8 and 
9). 
In addition to the formicamycins 4-16, we identified three 
related compounds (1-3) which lacked the two chiral centres 
at C10 (tertiary hydroxyl group) and C19 (bridgehead proton), 
and have an aromatic C-ring structure. These compounds were 
significantly more yellow than 4-16 with distinct UV spectra 
(with maxima at 246, 286, 353 and 418 nm) and exhibited 
significantly different optical rotations to the formicamycins. 
On the basis of these observations we assigned these 
compounds as new fasamycin congeners C-E (1-3) respectively. 
The fasamycins were first reported by Brady and co-workers in 
2011
15,20
 and 1-3 represent new members of this family. We 
hypothesise that 1-3 represent biosynthetic precursors of the 
formicamycin biosynthetic pathway as discussed below. 
      To unambiguously assign the pentacyclic skeleton of these 
metabolites and confirm their polyketide origin, we performed 
a stable isotope labelling experiment. S. formicae was 
cultivated on MS agar (2 L) in the presence of [1,2-
13
C2] sodium 
acetate. After 7 days incubation the agar was extracted and 
the most abundant congener was isolated (compound 4; 5 
mg). The resulting 
13
C NMR spectra clearly indicated the intact 
incorporation of 12 acetate derived units, plus an enriched 
single carbon at C24, in a pattern consistent with a polyketide 
biosynthetic pathway (see ESI Fig. S3). 
Stereochemistry of the fasamycins and formicamycins 
Our NMR data alone did not allow configurational analysis of 
the two families of compounds to be completed. Although 1-3 
lack any chiral centres they exhibit optical activity with [α]D
2
 
0 
values in the range +18° to +27°; this optical activity is due to 
preferred structures generated by rotation about the chiral 
axis of the C6-C7 bond. Additionally, the formicamycins have 
chiral centres at C10 and C19 which leads to a shift in 
aromaticity of ring-C consistent with the distinct UV spectra of 
these compounds, and they exhibit much larger magnitude 
optical rotations. 
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Fig. 3 Comparison of the experimental and calculated CD spectra of 3 (A) and 5 (B), and the lowest energy conformers of (S)-3 (C) and 
(10R,19R)-5 (D). The key NOESY correlations for 5 are shown. 
 
 
To aid in determining their stereochemistry the electronic 
circular dichroism (ECD) spectra of fasamycin 3 and 
formicamycin 5 were calculated using time-dependent density 
functional theory (TDDFT). First, a systematic conformational 
analysis of each isomer was carried out using the MMFFs 
molecular mechanics force field via the Maestro software 
package.
21
 The conformers obtained within an energetic range 
of 3 kcal.mol
-1
 of the lowest energy conformer were further 
optimized using the PBE1PBE
22
 exchange-correlation 
functional at the def2tzvp
23
 basis set level and with the SMD 
solvent model
24
 for methanol using the Gaussian09 program 
package.
25
 Frequency calculations were then carried out using 
these same settings to calculate the relevant percentage of the 
population of the conformers. The 30 lowest electronic 
transitions were then calculated using TDDFT and the 
rotational strengths of each electronic excitation were 
converted to ECD spectra using a Gaussian function with a 
half-bandwidth of 0.248 eV. The overall ECD spectra were then 
generated according to the Boltzmann weighting of each 
conformer. 
 For the fasamycins, rotation about the C6-C7 axis means 
ring-A can be drawn with either the ortho hydroxyl or methyl 
group pointing forwards which correspond to the S- or R-
configurations respectively. Comparison of the experimentally 
obtained ECD spectra for 3 to those calculated gives excellent 
agreement with that calculated for the S-configuration (Fig 3A 
and ESI Fig. S3) strongly suggesting this represents the 
preferred conformation.  
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For 5 we first compared the predicted structures for the 
lowest energy conformations of both the (10RS,19RS) and 
(10SR,19RS) diastereoisomeric pairs to data from NOSEY 
experiments. As observed in ESI Fig. S6 the (10SR,19RS) 
isomers with a trans relationship of the C10 and C19 
substituents adopt an extended conformation of the four 
fused rings B-E. In contrast the cis (10RS,19RS) isomers are 
predicted to adopt a twisted L-shaped conformation (Fig. 3). 
From this comparison the methine proton at C19 becomes 
diagnostic as the (10RS,19RS) isomers should show strong 
correlations to both methyl groups attached to C18 (methyl-
26/27), whereas for the (10SR,19RS) isomers it should only 
give a correlation to methyl-27. Analysis of the NOESY data 
shows strong correlations for both methyl groups (26/27), and 
the remaining correlation data are also consistent with that 
expected for the (10RS,19RS) isomers (see Figs. 2 and 3D). We 
then acquired additional NMR datasets for 5 in non-protic 
solvent (d6-DMSO/d3-acetonitrile) and were able to locate the 
signal for the exchangeable hydroxyl proton at C10. Analysis of 
the NOESY spectrum showed clear correlations for this proton 
to the methine proton at C19 and methyl-27 which is 
compatible with the cis (10RS,19RS) isomers, but not the trans 
(10SR,19RS) isomers. NOESY data for the remaining 
formicamycin congeners was also consistent with the cis 
(10RS,19RS) configuration in each case. On this basis we were 
able to rule out the trans (10SR,19RS) isomers and proceeded 
to analyse the calculated and experimentally determined ECD 
spectra for the cis (10R,19R) and (10S,19S) enantiomers of 5 
(Fig. 3A and ESI Figs. S4-S5). These data strongly suggested that 
the (10R,19R) stereochemistry was correct. Therefore, using 
combined NOESY NMR and ECD data we assign the (10R,19R) 
stereochemistry to the formicamycins. However, we are 
unable to make a definitive statement regarding the chiral C6-
C7 axis for the formicamycins. 
 
Formicamycins exhibit potent activity against Gram-positive 
bacteria including drug resistant clinical isolates 
To examine their structure activity relationship (SAR) we 
examined the growth of B. subtilis in liquid media 
supplemented with 0.01 – 100 µM of 1-15. The MIC for each 
compound against B. subtilis is shown in Table 1 and the 
growth curve for one of the most potent (12) is shown in Fig. 
4. All compounds effectively inhibit the growth of B. subtilis 
with an increase in potency observed for compounds 
containing an increasing number of chlorine atoms. 
Interestingly, brominated compounds appear to be slightly 
more potent than the equivalent chlorinated formicamycins. A 
shift from the fasamycin to formicamycin congeners also 
correlates with an increase in activity although it is unclear 
whether the ability to poly-halogenate this scaffold is the 
overriding factor.  
      To test whether 1-15 can inhibit drug-resistant Gram-
positive bacteria we tested them against clinical isolates of 
MRSA and vancomycin-resistant Enterococcus faecium (VRE) 
(see ESI) and found that the formicamycins are effective 
inhibitors of these organisms (Table 1). During the course of 
these experiments we observed that our test strains did not 
acquire spontaneous resistance when cultured on agar 
containing formicamycins. To test this further, we grew MRSA 
for four generations in the presence of no compound (control) 
and half MICs of compounds 6, 13 and 15. We then repeated 
the MIC tests and found no difference between the MRSA 
strains suggesting no resistance had arisen to formicamycins. 
We repeated the experiment but this time grew the strains for 
20 generations and again found no increase in the MICs for 
these compounds, suggesting they exhibit a high barrier for 
the selection of resistant mutants, at least under the 
conditions tested here. 
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Compound 
Minimum Inhibitory Concentration (µM) 
B. subtilis MRSA VRE 
1 <20 40 40 
2 10 10 10 
3 5 80 80 
4 5 >80 >80 
5 10 10 10 
6 5 1.25 80 
7 10 20 10 
8 10 20 10 
9 5 20 2.5 
10 5 Not tested Not tested 
11 10 Not tested Not tested 
12 <2.5 <2.5 1.25 
13 <20 0.625 1.25 
14 <2.5 2.5 5 
15 <2.5 1.25 2.5 
 
Table 1 MIC data for 1-15 against B. subtilis, and MRSA and 
VRE clinical isolates. Values indicating “Not tested” or with “<” 
or “>” indicate issues with compound availability and a 
decision not to test further concentrations, i.e. they represent 
the lowest/highest concentrations tested. 
 
Identification of the formicamycin BGC 
Based on their structures we predicted that biosynthesis of the 
formicamycins would be encoded by a BGC containing type 2 
polyketide synthase (PKS) genes. Analysis of the S. formicae 
genome using antiSMASH 3.0
13
 identified only one type 2 PKS 
gene cluster (BGC30) which we designate for (Fig. 5; Table S2; 
accession number: KX859301). We used the CRISPR/Cas9 
vector pCRISPomyces-2
26
 to delete the entire BGC30 and 
surrounding genes in order to generate the unmarked deletion 
strain S. formicae Δfor; deletion of the BGC was confirmed by 
PCR amplification and sequencing (see ESI). The wild-type 
strain and four independently generated S. formicae Δfor 
mutants were then grown in parallel under formicamycin 
producing conditions and subsequent LCMS(UV) analysis of 
extracts confirmed that fasamycin/formicamycins were not 
produced by the mutant strains (Fig. 6B and Fig. 6C). To ensure 
that loss of fasamycin/formicamycin biosynthesis was due to 
genome editing, and not other mutational events, we utilized a 
PAC (P1-derived artificial chromosome) library of the S. 
formicae genomic DNA which was custom made in pESAC13 by 
BioS&T Co. (Montreal, Canada). This was screened with three 
primer pairs (Table S1), amplifying fragments either side and in 
the centre of BGC30. A single clone carrying the entire BGC30 
(pESAC13-215-G) was introduced into one of the 
fasamycin/formicamycin-deficient mutants using tri-parental 
mating.
27
 LCMS(UV) analysis of the complemented strain 
alongside wild-type and mutant strains confirmed that 
fasamycin/formicamycin biosynthesis had been restored (Fig. 
6D), and we conclude that BGC30 encodes the biosynthesis of 
compounds 1-13 in S. formicae. 
 
ForV is a halogenase required for formicamycin biosynthesis 
Despite the identification of formicamycin congeners containing up 
to four halogen atoms we could identify only a single gene (forV) in 
BGC30 likely to encode a halogenase. Furthermore, analysis of the 
S. formicae genome identified only two further genes encoding 
potential halogenase enzymes that were associated with other 
BGCs (data not shown). ForV is a putative Flavin dependent 
halogenase, a family of enzymes which have been widely studied as 
catalysts involved in natural products biosynthesis,
28
and a 
homologue of forV is present in the fasamycin BGC.
15,20
  
To investigate its biosynthetic role we deleted the forV 
coding sequence using CRISPR-Cas9 methodology. Four 
independently isolated mutants were verified by PCR and 
sequencing, and extracts of the mutants grown on MS agar 
were analysed by LCMS(UV) (Fig. 6E). This showed 
accumulation of the non-halogenated fasamycin C (1) plus a 
new molecule with the same molecular formulae and UV 
spectrum indicating that it is a structural isomer of 1 
(presumably bearing an O-methyl group at either C5 or C23 
rather than at C3). The production levels of 1 by this mutant is 
approx. 188-fold that observed for the wild-type strain. 
Notably, no formicamycins could be observed in this extract. 
These data strongly suggest that ForV is responsible for the 
introduction of up to four halogen atoms. Genetic (in trans) 
complementation with the forV gene under the control of the 
native promoter re-established production of the halogenated 
compounds 2 and 3 and the formicamycins (Fig. 6F) indicating 
there was no polar effect or unanticipated genetic mutation 
introduced by the gene editing. 
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# Gene AA Annotation 
 
# Gene AA Annotation 
1 orf4 306 NAD-dependent epimerase/dehydratase 
 
23 forS 106 Monooxygenase/cyclase 
2 orf3 336 MarR family transcriptional regulator 
 
24 forT 342 O-Methyltransferase 
3 orf2 199 Hypothetical protein 
 
25 forU 119 Monooxygenase/cyclase 
4 orf1 170 Transposase 
 
26 forV 430 Halogenase 
5 forQ 422 Decarboxylase 
 
27 forW 341 O-Methyltransferase 
6 forP 217 β-Lactamase (metallohydrolase) 
 
28 forX 571 Monooxygenase 
7 forO 259 Exodeoxyribonuclease III 
 
29 forY 315 Oxidoreductase 
8 forN 590 Acylhydrolase 
 
30 forZ 172 MarR family transcriptional regulator 
9 forM 261 Methyltransferase 
 
31 forAA 513 MFS family transporter 
10 forL 113 PKS cyclase 
 
32 forBB 220 LuxR family response regulator 
11 forK 478 Na+/H+ exchanger 
 
33 forCC 417 Sensor histidine kinase 
12 forJ 149 MarR family transcriptional regulator 
 
34 orf6 321 ABC transporter 
13 forI 455 ACC biotin carboxylase 
 
35 orf7 284 ABC transporter permease 
14 forH 607 ACC carboxyl transferase 
 
36 orf8 529 Glutamate synthase 
15 forG 363 Sensor histidine kinase 
 
37 orf9 166 Hypothetical protein 
16 forF 219 LuxR family response regulator 
 
38 orf10 203 Hypothetical protein 
17 forE 171 ACC biotin carboxyl carrier protein 
 
39 orf11 164 Hypothetical protein 
18 forD 153 PKS cyclase/dehydratase 
 
40 orf12 247 Glutamate ABC transporter 
19 forC 96 PKS ACP 
 
41 orf13 310 ABC transporter substrate binding protein 
20 forB 415 KSβ 
 
42 orf14 214 ABC transporter permease 
21 forA 420 KSα 
 
43 orf15 289 ABC transporter permease 
22 forR 131 Cupin (cyclase/monooxygenase) 
     
 
Fig. 5 Organization of the formicamycin (for) BGC and annotation of putative gene products. ACC = acetyl-CoA carboxylase; PKS = 
polyketide synthase; MFS = major facilitator superfamily. 
 
 
 
 
Biosynthesis of the formicamycins 
Prior to this investigation no experiments regarding the 
biosynthesis of the fasamycins or formicamycins had been 
reported, although a pathway was proposed for the former 
based on sequencing of the fasamycin BGC and bioinformatics 
analysis.
15
 Based on the isotope feeding experiments, 
comparative bioinformatics and mutational analysis described 
above we are able to propose a biosynthetic pathway and 
assign putative functions to the BGC30 gene products (Fig. 5 
and Fig. 7). Bacterial type 2 PKSs are characterized by a 
minimal set of gene products composed of the heterodimeric 
β-ketosynthase (KS) pair KSα/KSβ and an acyl carrier protein 
which are critical in determining polyketide chain length and 
the overall topology of the ring system to be made. We 
propose that ForABC comprise the minimal PKS and produce a 
tridecaketide intermediate 17 which, through the action of the 
putative additional tailoring enzymes including PKS 
cyclase/dehydratases (ForD, ForL, ForR), a hydrolase (ForN) 
and a decarboxylase (ForQ), is converted into 18 and then 19.  
All of 1-16 contain two methyl groups at C18 which, in 
conjunction with biosynthetic studies on the related 
pentangular polyketide benastatin,
29
 suggests that the first 
post-PKS step will involve installation of the gem-dimethyl 
group at C18. Three putative methyltransferases are encoded 
in BGC30 (ForM, ForT, and ForW), and ForT has the highest 
sequence shared identity with BenF (66%/49%; CAM58795.1) 
which catalyses the gem-dimethylation step during benastatin 
biosynthesis and is likely to catalyse the equivalent reaction 
during fasamycin/formicamycin biosynthesis; this gene is also 
present in the fasamycin BGC
15
. Our inability to identify and 
isolate the putative intermediate 19, or indeed any congeners 
lacking the gem-dimethyl moiety, leaves open the possibility 
that this molecule may not exist as an enzyme free 
intermediate and that ForT might actually act upon an ACP-
bound intermediate which is then released and 
decarboxylated. Additionally, we did not isolate any congeners 
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Fig. 6 Deletion of BGC30 abolishes formicamycin biosynthesis, 
and forV encodes a halogenase gene. HPLC traces (250 nm) 
showing: (A) isolated formicamycins 1-13 (mixed); (B) S. 
formicae wild-type; (C) S. formicae ∆for; (D) S. formicae 
∆for/pESAC13-215-G; (E) S. formicae ∆forV; (F) S. formicae 
∆forV/forV. 
lacking a methoxy-group at C3 which suggests that O-
methylation at this positon occurs next and will be catalysed 
by one of the remaining methyltransferases ForM or ForW to 
yield 1. 
The accumulation of only 1 and a new isomer in the forV 
deletion mutant suggests that chlorination is the next step of 
the biosynthetic pathway and that it is essential to enable 
further post-PKS steps to occur in order to produce the 
formicamycins. This is consistent with the low levels of 1-3 
observed from the wild-type organism, and analysis of the 
chlorination patterns for 2-13 suggests that chlorination at C2 
or C22 is essential, with C22 likely being preferred to yield 2. 
Introduction of the tertiary hydroxyl group at C10 and 
modification of ring-C probably occurs next in the biosynthetic 
sequence. Moreover, as we only identified formicamycins 
containing both of these changes we propose that the 
transformations are linked, and may be catalyzed by the 
combined actions of the flavin dependent monooxygenase 
ForX and flavin dependent oxidoreductase ForY to yield 20. A 
second O-methylation at C23 most likely occurs next (to give 
21) as all formicamycins contain this change. It is currently 
unclear when the final O-methylation at C5 occurs. 
      Finally, the most abundant formicamycin congeners 
contain either three or four chlorine atoms located on three 
different rings, and the minor congeners contain mostly two or 
three chlorine atoms distributed around the various locations; 
no fasamycins have a chlorine atom on ring E. These 
observations are consistent with the idea that ForV is a 
promiscuous enzyme capable of catalysing up to four 
halogenation reactions on a single molecule, but that there is a 
preferred, but not absolute, ordering to these modifications. 
 Comparison to the fasamycin BGC
15
 fails to identify 
homologues of certain genes present in BGC30 that we 
propose may be involved in formicamycin biosynthesis. In 
contrast others are present in both BGCs that we suggest may 
be responsible for some of the structural differences observed. 
Plausible reasons for these differences include differential 
expression, or a lack of expression in one species, and the 
involvement of genes that were not captured on the 
expression cosmid used for production of the fasamycins.
15
 To 
address these questions a detailed study of formicamycin 
biosynthesis is underway in our labs. 
Conclusions 
Most of the antibiotics in clinical use are derived from the 
natural products of soil microbes, most notably species of 
Streptomyces bacteria that were discovered more than 50 
years ago. Here we highlight how searching under-explored 
environments combined with new advances in genome 
sequencing and editing enables the discovery of new species 
making natural products with potent anti-infective activity that 
could bypass resistance and form the basis of new anti-
infective therapies. Specifically, we identified a new species, 
Streptomyces formicae, from the African plant-ant 
Tetraponera penzigi, and show that it makes a family of rare 
pentangular polyketide antibiotics. These new molecules, 
which we call the formicamycins, inhibit the growth of the 
clinically relevant pathogens MRSA and VRE. The 
formicamycins are more potent than the previously reported 
and structurally related fasamycins.
15,20
 Spontaneous 
resistance to fasamycins was used to identify their molecular 
target but our data suggest that the formicamycins have a 
higher barrier for the selection of resistant mutants, at least 
for MRSA, under the conditions examined here. The reason for 
increased potency of the poly-halogenated congeners may 
simply be due to increased lipophilicity and an enhanced 
ability to cross the bacterial cell membrane. Moreover, 
docking studies reported during the previous work on 
fasamycins mode of action suggest that the chloro-gem-
dimethyl-anthracenone substructure represents the key 
pharmacophore.
20
  This region comprises the key structural 
differences between the two chemotypes as exemplified by 
the three dimensional structure presented in Fig. 3 and it is 
currently unclear whether their molecular target and mode of 
action may differ. This will be addressed in future studies. 
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Fig. 7 Proposed biosynthetic pathway for the fasamycins/formicamycins. Bold bonds in 17 indicate the positions of [
13
C2] sodium 
acetate units incorporated into the polyketide backbone.  
 
      Intriguingly, bioinformatics analysis shows that the 
formicamycin BGC is closely related to an unassigned BGC 
present in the genome of Streptomyces kanamyceticus 
(Genbank ID LIQU00000000.1). Further, an approx. 188 kbp 
region of the S. formicae genome, which encompasses BGC30, 
is syntenic with the S. kanamyceticus genome (extending 
approx. 64 kbp upstream and at least 95 kbp downstream, 
which is as far as the contig LIQU01000034 extends) and we 
suggest there has been a horizontal gene transfer event. 
Further bioinformatics analysis and consideration of the 
biosynthetic pathway leads us to propose that forQ and forCC 
represent the boundaries of BGC30 (Fig. 4). Additionally, the 
region of sequence encoding forX to forAA, which is not 
present on the S. kanamyceticus genome, comprises gene 
sequences with closest homologues in Actinomadura species, 
and appears to have been inserted into the S. kanamyceticus 
syntenic sequence. This suggests the formicamycin BGC may 
have its origin in multiple horizontal transfer events. Further 
work, both to understand the origins of the formicamycin BGC, 
and to delineate their biosynthesis, are underway in our 
laboratories. We anticipate this data will aid in the application 
of biosynthetic medicinal chemistry methods to produce 
further improved molecules with potential application as 
antibacterial agents. 
Materials and methods 
For details regarding experimental procedures, spectroscopic 
and chromatographic data, microbiology and molecular 
biology procedures, genome sequencing and the proposed 
function of gene products, see the electronic supplementary 
information. 
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